Sera Prognostics, Inc. · NASDAQ:SERA
Sera Prognostics — Q3 2026 Earnings Presentation
15 slides from Sera Prognostics's earnings presentation, Nov 4, 2026

Slide 1: 3Q26 Earnings Call
E A R N IN GS P R E SE NT A TI O N 3Q26 Earnings Call NOVEMBER 4, 2026 NASDAQ: SERA ©2026 Sera Prognostics, Inc. All rights reserved. Sera, PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States.

Slide 2: Safe Harbor Statement
This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue

Slide 3: Significant uptick in commercial adoption in 3Q26
Significant uptick in commercial adoption in 3Q26 SALES FORCE EXPANSION Testing volume has grown significantly since PRIME was published in January 2026. Start of PRETRM TESTS ORDERED ORDERING CLINICIANS FY26 +54% +175% +100% +34% Current ≈2x Q1 base Q1 base Q1 2026 Q2 2026 Q3 2026 Q1 2026 Q2 2026 Q

Slide 4: Expanding trend with state Medicaid coverage laws
Expanding trend with state Medicaid coverage laws ILLINOIS FLORIDA OTHER STATES ≈3M* Medicaid lives ≈4M** Medicaid lives • Proposed legislation in one additional state with a planned 1Q27 vote • ≈6M Medicaid lives ≈50,000 Medicaid births ≈90,000 • ≈90,000 Medicaid Medicaid births births • Active lob

Slide 5: CE Mark and first international revenue anticipated in FY27
CE Mark and first international revenue anticipated in FY27 OPPORTUNITY OUTSIDE THE U.S. Similar in size to the U.S. opportunity • Kit based product, run by partner labs – in discussions with potential partners • Mentioned in European Association of Perinatal Medicine guidelines • Working on CE Mark

Slide 6: Strategic imperatives for our success
Strategic imperatives for our success Demonstrating a repeatable Converting leading clinical evidence Driving capital-efficient growth and scalable commercial model into expanding market access Prove out how strong clinical evidence, Use a multi-tiered market access Maintain a disciplined approach t

Slide 7: Commercial Execution
Commercial Execution Lee Anderson Lee Anderson Chief Commercial Officer 30+ years in diagnostics Exact Sciences, Genomic Health ©2026 Sera Prognostics, Inc. All rights reserved. Sera, PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the Un

Slide 8: Focused execution strategy to capitalize on Illinois Medicaid Coverage
Focused execution strategy to capitalize on Illinois Medicaid Coverage FIELD TEAM 2 sales representatives + 1 MSL Illinois-specific education and outreach Hired in August COMMERCIAL FOCUS Target high-opportunity accounts Practices in high-Medicaid regions and high-volume physicians EARLY TRACTION 10

Slide 9: Florida Represents Second Major Commercial Opportunity
Florida Represents Second Major Commercial Opportunity FIELD TEAM 3 sales representatives + 1 MSL Florida-specific education and outreach Hired in 3Q26 and early 4Q26 COMMERCIAL FOCUS Target high-opportunity accounts Practices in high-Medicaid regions and high-volume physicians EARLY TRACTION Starte

Slide 10: Practice implementation – moving from physician conviction to durable ordering
Practice implementation – moving from physician conviction to durable ordering Key 1 2 3 4 5 Process Steps IDENTIFY EDUCATE COLLECT TRACK COORDINATE Patient eligibility Patient discussion Order & sample Result follow-up Care pathway Define criteria • flag eligible Simple script • expectations • Orde

Slide 11: Market Access
Market Access Tiffany Inglis, M.D. Tiffany Inglis, M.D. Chief Medical Officer 25+ years in direct care and the health care payer industry Elevance, Anthem ©2026 Sera Prognostics, Inc. All rights reserved. Sera, PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera

Slide 12: Multiple Paths to Coverage, led by state Medicaid
MARKET ACCESS STRATEGY Multiple Paths to Coverage, led by state Medicaid 1 STATE LEGISLATION 2 PRIVATE PAYERS State laws and fee schedules that open Medicaid reimbursement Plan by plan coverage decisions and partnership programs D E M O NST RAT ED D E MONSTRATED Illinois: state law requires Medicaid

Slide 13: Financial Update
Financial Update Scott Gleason Scott Gleason Chief Financial Officer 25+ years in diagnostics Myriad Genetics, OraSure, Neogen ©2026 Sera Prognostics, Inc. All rights reserved. Sera, PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the Uni

Slide 14: Financial Update – Sequential Growth and Reduced OPEX
Financial Update – Sequential Growth and Reduced OPEX Test Volume Revenue Operating Expenses -11% 40% 54% Q226 Q326 Q226 Q326 Q226 Q326 Cash & Cash Equivalents & Marketable securities of $72.8M sufficient to fund operations into FY29 ©2026 Sera Prognostics, Inc. All rights reserved. Sera, PreTRM, Se

Slide 15: Thank You
{ THANK YOU }
Source: 6ix earnings call
More decks from Sera Prognostics, Inc.
Q2 2026 Earnings Presentation38 slides · Aug 12, 2026
Q4 2025 Earnings Presentation38 slides · Mar 18, 2026
Investor Presentation (January 2026)38 slides · Jan 8, 2026
Investor Presentation (September 2025)31 slides · Sep 5, 2025
Technical Presentation (March 2025)25 slides · Mar 19, 2025
Corporate Update (January 2025)39 slides · Jan 31, 2025